Shanghai Shyndec Pharmaceutical Co., Ltd. Class A

Shanghai Shyndec Pharmaceutical Co., Ltd. Class A

SSSE:600420
8.01
CNY
-0.06
(-0.74%)
0.48EPS
24.93P/E
11.25BMarket Cap
Mar 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.04
2.39
9.5
8.22
7.68
10.37
11.6
12.23
13.58
12.62
9.48
8.16
6.98
5.99
Basic EPS, GAAP
0.12
0.17
0.56
0.43
0.46
0.65
0.62
0.63
0.55
0.61
0.54
0.81
0.7
0.34
Free Cash Flow per Basic Share
-0.27
-0.15
1.34
0.54
1.93
1.16
0.82
1.15
1.13
2.48
1.07
1.52
1.07
- -
Dividend per Share
0.05
0.08
0.68
0.42
0.41
0.24
0.31
0.2
0.21
0.18
0.15
0.22
0.32
0.05
Book Value per Share
0.85
1.01
3.37
4.96
5.56
6.44
7.39
7.92
8.37
10.03
9.24
9.85
10.27
10.26
Tangible Book Value per Share
0.68
0.76
2.32
3.91
4.51
5.45
6.4
7
7.55
9.16
8.51
9.06
9.44
9.39
Basic Weighted Avg Shares
1,151
1,151
946
1,110
1,110
1,092
1,051
1,027
1,027
1,027
1,273
1,341
1,341
1,341
Sales/Revenue/Turnover
2,350
2,749
8,988
9,126
8,518
11,321
12,199
12,556
13,945
12,959
12,070
10,938
9,363
8,028
Operating Margin (%)
9.18
11.7
14.29
13.29
13.48
9.74
10.25
10.22
8.76
7.31
8.88
16.43
13.7
9.14
Depreciation Expense
74
105
691
724
814
732
722
726
820
842
819
772
717
- -
Net Income, GAAP
133
190
530
477
516
706
656
649
568
628
692
1,084
942
451
Effective Tax Rate (%)
13.34
16.69
15.79
17.61
14.18
17.31
13.46
13.55
10.57
11.85
12.03
20.38
13.97
13.08
Profit Margin (%)
5.65
6.91
5.9
5.23
6.06
6.23
5.38
5.17
4.08
4.84
5.73
9.91
10.06
5.62
Working Capital
527
676
859
1,626
1,529
1,903
3,184
3,931
4,044
7,489
6,877
7,340
8,119
7,716
LT Debt
670
1,233
2,828
2,850
1,727
1,133
1,647
2,053
1,590
3,024
1,089
48
34
27
Total Equity
1,307
1,392
5,787
6,938
7,648
8,443
9,203
9,819
10,370
12,153
14,338
15,322
15,845
15,930
Return on Invested Capital (%)
7.27
7.83
12.32
6.59
6.64
8.73
6.87
6.62
5.92
5.75
6.11
8.71
6.97
4.04
Return on Capital (%)
4.67
6.65
3.66
3.04
3.65
4.34
4.27
3.8
3.07
3.27
3.03
5.41
4.61
1.67
Return on Common Equity (%)
13.55
17.7
21.01
9.95
8.69
10.87
9.12
8.26
6.8
6.64
6.1
8.47
6.98
3.3

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
9
9
7
LT Borrowings
- -
- -
- -
LT Finance Leases
29
29
27
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,341
1,341
1,341
Market Capitalization
14,230
10,662
11,252

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
11,413
11,255
10,927
Cash, Cash Equivalents & STI
3,724
3,513
4,139
Accounts Receivable, Net
1,208
1,180
1,078
Inventories
1,849
1,905
1,999
Total Current Liabilities
3,177
3,190
3,211
Payables & Accruals
- -
- -
- -
ST Debt
9
9
7
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.73%
10.21%
3.41%
Free Cash Flow
26.15%
18.26%
-29.56%
Net Income, GAAP
7.86%
10.36%
-13.11%
Sales/Revenue/Turnover
1.18%
-5.33%
-14.39%
Total Cash Common Dividend
0.79%
18.32%
42.31%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,123
2,837
2,633
2,344
10,938
2025
2,607
2,271
- -
2,443
9,363
2026
2,064
1,876
1,645
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.25
0.29
0.18
0.1
0.81
2025
0.27
0.23
- -
0.1
0.7
2026
0.1
0.1
0.03
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.1
0.1
- -
0.22
2025
0.02
-0.01
- -
- -
0.32
2026
- -
- -
0.05
- -
- -

Company Description

CEO
Yong Liu
Full Time Employees
9,697
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 378, Jianlu Road Shanghai SH China 200137
IPO Date
Jun 16, 2004
Business
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products primarily in China. The company manufactures and distributes a diverse portfolio including pharmaceutical intermediates and active pharmaceutical ingredients such as 6-APA, 7-ADCA, 7-ACA, D-7ACA, penicillin industrial potassium, amoxicillin, clavulanic acid series, azithromycin, and ceftriaxone sodium; chemical preparations encompassing systemic anti-infectives, cardiovascular medications like nifedipine controlled release tablets, urogenital system drugs and hormones, central nervous system agents, musculoskeletal treatments such as diclofenac sodium sustained-release tablets, digestive tract and metabolism medications, anti-tumor and immunomodulators, blood and hematopoietic system drugs, and respiratory system medications; urine-derived biochemical products; animal vaccines; and general health products including garlic oil soft capsules and lecithin soft capsules. Founded in 1996 by academicians of the Chinese Academy of Engineering and headquartered at No. 378 Jianlu Road, Pudong New District, Shanghai, China, the company listed on the Shanghai Stock Exchange in June 2004 and joined China Pharmaceutical Group Co., Ltd. in April 2010 as a subsidiary, employing approximately 11,472 people and operating within the healthcare sector focused on drug manufacturing for specialty and generic pharmaceuticals. Recent developments include ongoing investments in research and development to expand its pipeline across therapeutic areas such as infectious diseases, cardiovascular conditions, and anti-tumor treatments, alongside maintenance of strategic relationships within the China Pharmaceutical Group ecosystem to support distribution and supply chain efficiency.